Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome.
CONCLUSIONS: Stiripentol is an effective adjunctive therapy for reducing the frequency and duration of refractory seizures in patients with Dravet syndrome. Its role in the treatment of other refractory epilepsies requires further study.
PMID: 31167540 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Buck ML, Goodkin HP Tags: Ann Pharmacother Source Type: research
More News: Anorexia | Drugs & Pharmacology | Eating Disorders & Weight Management | Epilepsy | Genetics | Sodium | Study | USA Health